Design of a Chimeric Multi-Epitope Vaccine (CMEV) against Both Leishmania martiniquensis and Leishmania orientalis Parasites Using Immunoinformatic Approaches.

Abstract

Simple SummaryLeishmaniasis, caused by parasites from the genus Leishmania, is one of the neglected tropical diseases that is particularly problematic in tropical regions. Vaccine development is anticipated, but the diversity of pathogens poses a challenge. In this study, we designed a vaccine that is expected to be effective against both Leishmania martiniquensis and Leishmania orientalis, two different species isolated in Thailand. Predicted antigenic proteins and their epitopes were extracted from the draft genomes of these two species, and a chimeric multi-epitope vaccine was constructed in silico. The immunogenicity, chemical, and structural properties of the designed protein molecules suggest that this molecule could be properly synthesized in a heterologous expression system and induce responses in the inoculated host immune system. Based on these results, further experiments are required to determine the practical application of this vaccine candidate.Leishmaniasis is a parasitic disease caused by protozoan flagellates of the genus Leishmania. Recently, Leishmania martiniquensis and Leishmania orientalis, emerging species of Leishmania, were isolated from patients in Thailand. Development of the vaccine is demanded; however, genetic differences between the two species make it difficult to design a vaccine that is effective for both species. In this study, we applied immuno-informatic approaches to design a chimeric multi-epitope vaccine (CMEV) against both L. martiniquensis and L. orientalis. We identified seven helper T lymphocyte (HTL) epitopes, sixteen cytotoxic T lymphocyte (CTL) epitopes, and eleven B-cell epitopes from sixteen conserved antigenic proteins found in both species. All these epitopes were joined together, and to further enhance immunogenicity, protein and peptides adjuvant were also added at the N-terminal of the molecule by using specific linkers. The candidate CMEV was subsequently analyzed from the perspectives of the antigenicity, allergenicity, and physiochemical properties. The interaction of the designed multi-epitope vaccine and immune receptor (TLR4) of the host were evaluated based on molecular dockings of the predicted 3D structures. Finally, in silico cloning was performed to construct the expression vaccine vector. Docking analysis showed that the vaccine/TLR4 complex took a stable form. Based on the predicted immunogenicity, physicochemical, and structural properties in silico, the vaccine candidate was expected to be appropriately expressed in bacterial expression systems and show the potential to induce a host immune response. This study proposes the experimental validation of the efficacy of the candidate vaccine construct against the two Leishmania.